Inhibition of P-glycoprotein transport function by N-acylphenothiazines

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2863-2868

  Wesolowska, Olga ^a   Molnár, Joseph ^b   Motohashi, Noboru ^c   Michalak, Krystyna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF SZEGED   (Hungary)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Flow cytometry; Multidrug resistance; P glycoprotein; Phenothiazine derivatives

Indexed keywords

GLYCOPROTEIN P; PHENOTHIAZINE ACETYLAMIDE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PHENOTHIAZINE MALEATE DERIVATIVE; PHENOTHIAZINE METHOXYCARBONYLAMIDE DERIVATIVE; PHENOTHIAZINE METHYLSULFONYLAMIDE DERIVATIVE; RHODAMINE 123; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL ASSAY; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; FLOW CYTOMETRY; HYDROPHOBICITY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT;

ANIMALS; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; GENES, MDR; LEUKEMIA L5178; MICE; P-GLYCOPROTEIN; PHENOTHIAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036765439     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bosch I and Croop J: P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1288: F37-F54, 1996.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398, 1999.
3. Motohashi N, Kawase M, Saito S and Sakagami H: Antitumor potential and possible targets of phenothiazine-related compounds. Curr Drug Targets 1: 237-245, 2000.
4. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733, 1982.
5. Ganapathi R, Grabowski D and Schmidt H: Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. Biochem Pharmacol 35: 673-678, 1986.
6. Ramu A and Ramu N: Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30: 165-173, 1992.
7. Ford JA, Prozialeck WC and Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115, 1989.
8. Pajeva I and Wiese M: Molecular modelling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J Med Chem 41: 1815-1826, 1998.
9. Molnár J, Pusztai R, Hever A, Nagy S and Motohashi N: Effects of two benzo[a]phenothiazines on multi-drug resistance (mdr) and tumor antigen expression. Anticancer Res 15: 2013-2016, 1995.
10. Molnár J, Hever A, Fakla I, Fischer J, Ocsovski I and Aszalos A: Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res 17: 481-486, 1997.
11. Motohashi N, Kurihara T, Kawase M, Hever A, Tanaka M, Szabo D, Nacsa J, Yamanaka W, Kerim A and Molnar J: Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines. Anticancer Res 17: 3537-3543, 1997.
12. Moinár J, Szabo D, Mandi Y, Mucsi I, Fischer J, Varga A, Koenig S and Motohashi N: Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res 18: 3033-3038, 1998.
13. Motohashi N, Kawase M, Saito S, Kurihara T, Satoh K, Nakashima H, Premanathan M, Arakaki R, Sakagami H and Molnár J: Synthesis and biological activity of N-acylphenothiazines. Int J Antimicr Agents 14: 203-207, 2000.
14. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutheford AV and Willingham MC: A retrovirus carrying an MDR-1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Sci USA 85: 4486-4490, 1988.
15. Weaver JL, Szabo G, Pine PS, Gottesman MM, Goldenberg S and Aszalos A: The effect of ion channel blockers, immunosupressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer 54: 456-461, 1993.
16. Zamora JM, Pearce HL and Beck WT: Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462, 1988.
17. Frenzel J, Arnold K and Nuhn P: Calorimetric, 13C NMR, and 31P NMR studies on the interaction of some phenothiazine derivatives with dipalmitoyl phosphatidylcholine model membranes. Biochim Biophys Acta 507: 185-197, 1978.
18. Nerdal W, Gundersen SA, Thorsen V, Hoiland H and Holmsen H: Chlorpromazine interaction with glycerophospholipid liposomes studied by magic angle spinning state 13C-NMR and differential scanning calorimetry. Biochim Biophys Acta 1464: 165-175, 2000.
19. Hendrich AB, Wesolowska O and Michalak K: Trifluoperazine induces domain formation in zwitterionic phosphatidylcholine but not in charged phosphatidylglycerol bilayers. Biochim Biophys Acta 1510: 414-425, 2001.
20. Varnier Agasoster A, Tungodden LM, Cejka D, Bakstad E, Sydnes LK and Holmsen H: Chlorpromazine-induced increase in dipalmitoylphosphatidylserine surface area in monolayers at room temperature. Biochem Pharmacol 61: 817-825, 2001.
21. Varnier Agasoster A Holmsen H: Chlorpromazine associates with phosphatidylserines to cause an increase in lipid's own interfacial molecular area - role of the fatty acid composition. Biophys Chem 91: 37-47, 2001.
22. Isomaa B, Hagerstrand H and Paatero G: Shape transformations induced by amphiphiles in erythrocytes. Biochim Biophys Acta 899: 93-103, 1987.
23. Hagerstrand H and Isomaa B: Vesiculation induced by amphiphiles in erythrocytes. Biochim Biophys Acta 982: 179-186, 1989.
24. Pajeva IK, Wiese M, Cordes HP and Seydel JK: Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol 122: 27-40, 1996.
25. Wadkins RM and Houghton PJ: The role of drug-lipid interactions in the biological activity of modulators of multi-drug resistance. Biochim Biophys Acta 1153: 225-236, 1993.
26. Motohashi N, Kurihara T, Yamanaka W, Satoh K, Sakagami H and Molnár J: Relationship between biological activity and dipole moment in benzo[a]phenothiazines. Anticancer Res 17: 3431-3435, 1997.
27. Kurihara T, Motohashi N, Sakagami H and Molnár J: Relationship between cytotoxic activity and dipole moment for phthalimido- and chloroethyl-phenothiazines. Anticancer Res 19: 4081-4083, 1999.
28. Nacsa J, Nagy L, Sharples D, Hever A, Szabo D, Ocsovszki I, Varga A, Konig S and Molnár J: The inhibition of SOS-responses and MDR by phenothiazine-metal complexes. Anticancer Res 18: 1373-1376, 1998.
29. Molnár J, Tarodi B, Galfi M, Matkovics B and Motohashi N. In vitro antiproliferative effects of tricyclic psychopharmaceutical, agents and synergism with some resistance modifiers. Anticancer Res 12: 273-280, 1992.
30. Seeman PM and Bialy HB: The surface activity of tranquilizers. Biochem Pharmacol 12: 1181-1191, 1963.
31. Dea PK, Keyzer H and Maurer JS: Structure-activity relationships of phenothiazines and 1,4-benzothiazines. In: Phenothiazines and 1,4-benzothiazines, chemical and biomedical aspects (Gupta RR, ed). Amsterdam, Elsevier, 1988, pp 587-626.